Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

Phase 4 Unknown 122 enrolled Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, biomarker-driven, open-label, clinical trial of osimertinib in treatment- naïve patients with EGFR mutant NSCLC, to evaluate the efficacy of osimertinib according to the TP53 mutational status.

Timeline

Start: 2022-06-28
Primary completion: 2024-02-28
Completion: 2025-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Osimertinib	Small molecule	80 mg	—

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

Summary

Timeline

Drugs

Indications